CUAMC
MRTX

China Universal Asset Management Company’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

China Universal Asset Management Company’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8,117
Closed -$477K – 458
2023
Q4 		$477K Buy
8,117
+6,365
+363% +$358K 0.09% 150
2023
Q3 		$76.3K Buy
1,752
+990
+130% +$35.3K 0.02% 211
2023
Q2 		$27.5K Sell
762
-24
-3% -$989 0.01% 241
2023
Q1 		$29.2K Buy
786
+201
+34% +$9.04K 0.01% 186
2022
Q4 		$26.5K Buy
585
+64
+12% +$4.14K 0.01% 160
2022
Q3 		$36K Buy
+521
New +$38.6K 0.02% 131
2022
Q2 		– Sell
-247
Closed -$20K – 99
2022
Q1 		$20K Sell
247
-15,853
-98% -$1.62M 0.01% 76
2021
Q4 		$2.36M Buy
+16,100
New +$2.5M 0.56% 57

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

China Universal Asset Management Company's MRTX Position: Q1 2024 in Review

China Universal Asset Management Company sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 8,117 shares — an estimated $477K sold.

China Universal Asset Management Company first reported a position in MRTX in Q4 2021 and held it in 8 quarters. The position peaked at $2.36M in Q4 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • China Universal Asset Management Company reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • China Universal Asset Management Company sold 8,117 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $477K.
  • China Universal Asset Management Company first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
  • China Universal Asset Management Company's Mirati Therapeutics, Inc. Common Stock position peaked at $2.36M in Q4 2021.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on China Universal Asset Management Company's 13F filing for Q1 2024, filed 29 Apr 2024.